The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1298-1305

  Filipits, Martin ^a   Nielsen, Torsten O ^m   Rudas, Margaretha ^a   Greil, Richard ^d   Stoger, Herbert ^f   Jakesz, Raimund ^a   Bago Horvath, Zsuzsanna ^a   Dietze, Otto ^e   Regitnig, Peter ^g   Gruber Rossipal, Christine ^h   Muller Holzner, Elisabeth ⁱ   Singer, Christian F ^b   Mlineritsch, Brigitte ^d   Dubsky, Peter ^a   Bauernhofer, Thomas ^f   Hubalek, Michael ⁱ   Knauer, Michael ^h   Trapl, Harald ^j   Fesl, Christian ^c   Schaper, Carl ^k   Ferree, Sean ^l   Liu, Shuzhen ^m   Cowens, J Wayne ^l   Gnant, Michael ^a   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c Austrian Breast and Colorectal Cancer Study Group   (Austria)

^d Departments of Internal Medicine III   (Austria)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f Departments of Internal Medicine   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h SISTERS OF CHARITY HOSPITAL   (Austria)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j Hospital Baden   (Switzerland)

^k Myraqa   (United States)

^l NANOSTRING TECHNOLOGIES   (United States)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; OUTCOME ASSESSMENT; PAM50 GENE; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RNA ANALYSIS; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84895800618     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1845     Document Type: Article

References (24)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
2. Yu KD, Wu J, Shen ZZ, Shao ZM. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab 2012;97:E2201-9.
3. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
4. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845-53.
5. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-71.
6. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Longterm effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
7. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, EarlHM, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013 (31suppl; abstr 5).
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
10. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
11. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011;17:6012-20.
12. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
13. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16:5222-32.
14. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens JW, et al. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting risk of recurrence and distant recurrence after endocrine therapy. J Clin Oncol 2013;31:2783-90.
15. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of theABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2013 doi: 10.1093/annonc/mdt494.
16. Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M. Prediction of late breast cancer recurrence by the ROR(PAM50) score in postmenopausal women in the TransATAC cohort. Ann Oncol 2012;23 Suppl. 9:75-6.
17. Sestak I, Dowsett M, Sgroi D, Erlander M, Ferree S, Cowens JW, et al. Comparison of five different scores for the prediction of late recurrence for oestrogen receptor-positive breast cancer. Ann Oncol 2013;24 Suppl. 3:29.
18. Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, et al. The EndoPredict score identifies late distant metastases in ER+/HER2-breast cancer patients. Cancer Res, 2012;72:101s.
19. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG,et al. Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptorpositive lymph node-negative breast cancer patients: a TransATAC study. Cancer Res, 2012;72:92s-3s.
20. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breastcancer toanastrozole after 2 years'adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
21. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012;30:722-8.
22. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-25.
23. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol 2011;Chapter 25: Unit25B10.
24. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101:1446-52.